As of Jan. 14, 2,668 individuals in the United States and its territories have been hospitalized with e-cigarette, or vaping, product use-associated lung injuries (EVALIs). Nevertheless, the Centers for Disease Control and Prevention (CDC) has softened its approach toward e-cigarettes such that its new recommendations practically endorse e-cigarette use by certain populations. This article examines the CDC’s abrupt change in position on e-cigarettes and analyzes the efficacy of the CDC’s new guidance.
The CDC’s Retreat From Common Sense
On Aug. 30, 2019, the CDC issued a health advisory related to e-cigarette use. That advisory included recommendations for clinicians, public health official, and the public at large. The first recommendation issued to the public was straightforward without being alarmist: “While this investigation is ongoing, if you are concerned about the specific health risks associated with e-cigarettes, consider refraining from using e-cigarette products.” On Jan. 17, the CDC abandoned that message.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]